- Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies. - Series A funding closed at $61m. - The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). - The new investment will be used to advance the company's pipeline programs towards clinical development.

- Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies. - Series A funding closed at $61m. - The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). - The new investment will be used to advance the company's pipeline programs towards clinical development.

– Synthekine closed an oversubscribed $107.5m Series B financing.
– The round was co-led by Deerfield Management and Janus Henderson Investors, with participation from RA Capital Management, Rock Springs Capital, Omega Funds, TCG X, Lilly Asia Ventures, and an undisclosed leading healthcare investor.
– Existing investors The Column Group, Samsara BioCapital, Canaan Partners, and Emerson Collective also participated in the round.
– Synthekine is advancing cytokine science and creating optimized therapeutics in this important space.
– Synthekine expects to move both programs into clinical investigation within the next year, with proceeds from the financing supporting clinical proof-of-concept data.

– Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the completion of a $336m Series C financing led by RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor.
– Existing investors Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab and Omega Funds also participated in the financing.

– Icosavax closed a $100m Series B Financing, led by RA Capital Management and joined by Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, and Surveyor Capital (a Citadel company).
– A previously announced funding from Open Philanthropy was included in this round.
– The proceeds of the financing will support the development of Icosavax’s bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine program through initial clinical studies, continued evaluation of its SARS-CoV-2 vaccine candidate, and further expansion of the company’s pipeline of VLP vaccine candidates focused on protecting older adults from life-threatening respiratory diseases.

– Amunix Pharmaceuticals from South San Francisco develops masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers.
– Series B $117m round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management and existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital, and Polaris Partners.